Perrigo/$PRGO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Perrigo
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Ticker
$PRGO
Sector
Primary listing
NYSE
Employees
8,379
Headquarters
Dublin, Ireland
Website
Perrigo Metrics
BasicAdvanced
$2.9B
-
-$0.58
0.43
$1.15
5.43%
Price and volume
Market cap
$2.9B
Beta
0.43
52-week high
$30.93
52-week low
$20.52
Average daily volume
1.9M
Dividend rate
$1.15
Financial strength
Current ratio
2.322
Quick ratio
1.031
Long term debt to equity
85.014
Total debt to equity
81.656
Interest coverage (TTM)
2.36%
Profitability
EBITDA (TTM)
863.8
Gross margin (TTM)
35.72%
Net profit margin (TTM)
-1.85%
Operating margin (TTM)
12.39%
Effective tax rate (TTM)
157.54%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
3.27%
Return on equity (TTM)
-1.32%
Valuation
Price to revenue (TTM)
0.682
Price to book
0.66
Price to tangible book (TTM)
-1.87
Price to free cash flow (TTM)
11.926
Free cash flow yield (TTM)
8.38%
Free cash flow per share (TTM)
1.793
Dividend yield (TTM)
5.36%
Forward dividend yield
5.43%
Growth
Revenue change (TTM)
-2.31%
Earnings per share change (TTM)
-36.40%
3-year revenue growth (CAGR)
-0.14%
3-year earnings per share growth (CAGR)
-12.64%
3-year dividend per share growth (CAGR)
4.59%
What the Analysts think about Perrigo
Analyst ratings (Buy, Hold, Sell) for Perrigo stock.
Bulls say / Bears say
Perrigo’s FDA approval and launch of a store-brand equivalent to Flonase expands its OTC portfolio and provides access to the allergy treatment market, potentially driving revenue growth. (Reuters)
The company’s tentative FDA approval for a generic version of Soolantra cream positions Perrigo to enter the high-value rosacea treatment segment, enhancing its generics pipeline. (Reuters)
The Flonase store-brand equivalent faces entrenched competition in the crowded OTC allergy market, which could pressure pricing and margins. (Reuters)
The generic Soolantra cream will compete against established dermatology players, heightening the risk of price erosion and limited market share. (Reuters)
Divesting its U.K. generic prescription pharmaceuticals business narrows Perrigo’s portfolio focus, increasing its exposure to consumer self-care cyclicality and reducing revenue diversification. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Perrigo Financial Performance
Revenues and expenses
Perrigo Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Perrigo stock?
Perrigo (PRGO) has a market cap of $2.9B as of October 16, 2025.
What is the P/E ratio for Perrigo stock?
The price to earnings (P/E) ratio for Perrigo (PRGO) stock is 0 as of October 16, 2025.
Does Perrigo stock pay dividends?
Yes, the Perrigo (PRGO) stock pays dividends to shareholders. As of October 16, 2025, the dividend rate is $1.146 and the yield is 5.43%. Perrigo has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Perrigo dividend payment date?
The next Perrigo (PRGO) dividend payment date is unconfirmed.
What is the beta indicator for Perrigo?
Perrigo (PRGO) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.